Tesamorelin

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It consists of the full 44-amino-acid sequence of GHRH with a stabilising N-terminal modification, a trans-3-hexenoyl group attached to the N-terminal tyrosine, which renders it more resistant to enzymatic degradation than the unmodified parent peptide.

Of all GHRH analogs in this database, tesamorelin carries the most clinically mature dossier: multiple phase III randomised trials and a still-active drug registration.

The compound has been studied predominantly in one specific clinical population (adults with HIV-associated abdominal fat accumulation) where it selectively reduces visceral adipose tissue. The strength of that evidence does not extend automatically to other populations or contexts.

As with all entries in the Peptalis database, this profile summarises the current state of research and does not constitute efficacy claims or product recommendations.

Mechanism of action

Tesamorelin acts on the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, stimulating endogenous pulsatile growth hormone release. The stabilised N-terminal modification confers resistance to enzymatic cleavage relative to native GHRH. Downstream, the GH/IGF-1 axis drives lipolysis with measurable selectivity for visceral over subcutaneous adipose tissue.

GHRH receptor activation

• Binds the pituitary GHRH receptor with potency comparable to endogenous GHRH
• Stimulates endogenous, pulsatile GH synthesis and release
• Trans-3-hexenoyl N-terminal modification extends duration of action relative to unmodified GHRH(1-44)

Downstream metabolic effects

• GH-driven IGF-1 elevation (a measured and expected consequence of pituitary stimulation)
• Selective reduction of visceral adipose tissue; subcutaneous fat is not meaningfully changed
• Triglyceride and cholesterol parameters improved in trials; glucose homeostasis was not impaired

Reversibility and dependency

• Effects on visceral adipose tissue are maintained while treatment continues
• Visceral fat returns after discontinuation, indicating the effect requires ongoing administration
• Mechanism is endogenous: pituitary feedback via somatostatin and IGF-1 is preserved

Research findings

• In two phase III RCTs in adults with HIV-associated abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by ~15% over 26 weeks while VAT increased in the placebo arm (Falutz 2007, n=412; Falutz 2010, n=404).
• The effect was selective for visceral fat; subcutaneous fat did not change meaningfully.
• Reduction was maintained through 12 months of continued treatment, but visceral fat returned after discontinuation; the effect requires ongoing administration.
• Triglycerides and cholesterol improved; glucose homeostasis was preserved. IGF-1 rose substantially, as expected from GH stimulation.
• In a later randomised study, tesamorelin also reduced hepatic fat and slowed progression of liver fibrosis in HIV-associated NAFLD (Stanley/Fourman 2020).

Metabolic research context

• In two phase III RCTs (Falutz 2007, n=412; Falutz 2010, n=404), tesamorelin reduced visceral adipose tissue by ~15% over 26 weeks vs an increase in placebo, in adults with HIV-associated abdominal fat accumulation.
• The effect was selective for visceral fat; subcutaneous fat did not change meaningfully.
• Through 12 months of continued treatment the reduction was maintained, but visceral fat returned after discontinuation. Effect requires ongoing administration.
• Triglycerides and cholesterol improved; glucose homeostasis was preserved. IGF-1 rose substantially as a direct consequence of GH stimulation.
• In a later randomised study, tesamorelin reduced hepatic fat and slowed liver fibrosis progression in HIV-associated NAFLD (Fourman/Stanley 2020).

Regulatory status

• Approved by the US FDA in November 2010 under the brand name Egrifta, specifically for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Still marketed.
• Not approved by the EMA; tesamorelin has no medicines registration in the European Union.
• Approval is restricted to this specific indication and population. The compound is expressly not approved for weight loss or for general growth hormone deficiency.

Research context

Tesamorelin carries the most clinically mature dossier of any GHRH analog in this database, anchored by multiple phase III trials with imaging-based endpoints and an active drug registration.

The evidence is strong within one well-defined clinical context, but that boundary matters: the favourable effects were demonstrated in a specific patient population and do not automatically translate to other contexts or to healthy users. That tesamorelin has progressed further in clinical development than most GHRH analogs does not make the findings broadly generalisable.

Even within a more mature evidence base, careful scope control is required. Readers may overextend findings beyond their original research frame.

Open questions

Tesamorelin's evidence base is unusually mature for a peptide in this category, but that maturity is bounded to one indication and one population. Interpretation outside that frame is not supported.

• Phase III evidence is concentrated in one clinical population (HIV-associated abdominal fat accumulation); generalisation beyond that context is not established
• No EMA registration; European regulatory review has not occurred
• Long-term data beyond ~12 months remain limited
• Effect is dependent on continued administration; durable benefit after discontinuation is not supported
• Direct head-to-head comparisons against other GHRH analogs under standardised conditions are incomplete
• Preclinical data is comparatively underrepresented relative to the human dossier

Research outlook

Further investigation of hepatic outcomes (NAFLD/NASH) following the Fourman 2020 signal

Long-term outcome data beyond 12 months and beyond the HIV-lipodystrophy population

Systematic comparison with other GHRH analogs under standardised research conditions

Mechanistic work on the selectivity for visceral over subcutaneous adipose tissue

Scientific interest

The most clinically mature GHRH analog in this database, anchored by multiple phase III RCTs

FDA-approved for one specific indication (HIV-associated lipodystrophy); not EMA-registered

Selective visceral fat reduction in a defined population, demonstrated with imaging endpoints

Reference point for evidence hierarchy and scope control within the GH-axis peptide category

Specifications

References

1. Metabolic effects of a growth hormone-releasing factor in patients with HIV · Falutz J, Allas S, Blot K, et al. · N Engl J Med · 2007
2. Tesamorelin, a human growth hormone releasing factor analogue · Wang Y, Tomlinson B · Expert Opinion on Investigational Drugs · 2009
3. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension · Falutz J, Potvin D, Mamputu JC, et al. · J Acquir Immune Defic Syndr · 2010
4. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy · Dhillon S · Drugs · 2011
5. Tesamorelin · Grunfeld C, Dritselis A, Kirkpatrick P · Nature Reviews Drug Discovery · 2011
6. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD · Fourman LT, Billingsley JM, Agyapong G, Stanley TL, Grinspoon SK, et al. · JCI Insight · 2020

Availability

Not in catalogue · Profile complete · verification and sourcing not yet finished